Alembic Pharmaceuticals net profit rises 15% to INR 154cr

Alembic Pharmaceuticals reported a 15% increase in net profit to INR 154 crore for Q1 FY26, with total revenue rising 10% to INR 1,711 crore.

The India branded business grew 5% to INR 599 crore, while US generics increased 13% to INR 523 crore. Ex-US international generics saw the strongest growth at 21% to INR 328 crore.

The company achieved 223 cumulative ANDA approvals, including six final approvals in the quarter.